21 Sep 2021 | 02:45 PM GMT
Past Meeting

Sprint: Prescription DTx - Commercialization Models & Adoption

Participants:

Lee Shapiro Managing Partner7wireVenturesInvestor & Accelerators
Investor & Accelerators
Lee Shapiro
Managing Partner7wireVentures
Zina Manji Founder/Principal, Regulatory StrategistInnopathwayz, LLCLife Sciences, Pharma & Biotech
Life Sciences, Pharma & Biotech
Zina Manji
Founder/Principal, Regulatory StrategistInnopathwayz, LLC
Chandana Fitzgerald President, CommunityHLTHOther
Other
Chandana Fitzgerald
President, CommunityHLTH
Aahuti Rai Health Innovation Leader & Venture PartnerFour Points HealthHealth Tech & Solutions
Health Tech & Solutions
Aahuti Rai
Health Innovation Leader & Venture PartnerFour Points Health
Ashley Mateus VP Consumer InsightsAkili Interactive Labs
Ashley Mateus
VP Consumer InsightsAkili Interactive Labs
Brendan Staunton CEOAmara Therapeutics
Brendan Staunton
CEOAmara Therapeutics
Chris Cera CEOArcweb TechnologiesHealth Tech & Solutions
Health Tech & Solutions
Chris Cera
CEOArcweb Technologies
Francesca Wuttke Founder & CEOnen HealthStartup
Startup
Francesca Wuttke
Founder & CEOnen Health
Jeff Berkowitz CEORealEndpoints
Jeff Berkowitz
CEORealEndpoints
JM
john mattison CMIOACPHealth System & Providers
JM
Health System & Providers
john mattison
CMIOACP
Joseph Rubinsztain CEOChronWell
Joseph Rubinsztain
CEOChronWell
Justin Norden PartnerGSR VenturesOther
Other
Justin Norden
PartnerGSR Ventures
Matt Norton VP of Marketing & Commercial DevelopmentS3 Connected HealthProfessional Services
Professional Services
Matt Norton
VP of Marketing & Commercial DevelopmentS3 Connected Health
Mike Pace Founder & CEOPalmHealthCoProfessional Services
Professional Services
Mike Pace
Founder & CEOPalmHealthCo
Robert Garber Managing Partner7wireVenturesInvestor & Accelerators
Investor & Accelerators
Robert Garber
Managing Partner7wireVentures

About this Meeting

In the past 2 years a wide variety of companies have co-opted the term “DTx” to describe their digital health offerings. In this meeting we want to focus on a smaller subset of this group: prescription digital therapeutics (PDTs), which are seen as the future of the DTx market. This series of 2 meetings to discuss with other senior leaders the following: 

  •  Session 1 (September 1st): Commercialization models Even though some PDT companies choose the traditional pharmaceutical pathway (salesforce-based), are Pharma-PDT partnerships the best efficient commercialization model for PDT companies? What are the alternatives? New consumer-focused telemedicine approaches to PDT distribution have recently entered the market. What are the pros & cons of this model?  How does the prescription pathway influence the product pricing? 
  •  Session 2 (September 21st): Adoption  As PDTs are edging closer to becoming incorporated into therapeutic arsenals, the seamless integration into conventional pathways still needs to be ironed out. How can digital health formularies and/or prescription platforms help in PDT adoption?  In some countries, there is prescription capability (e.g Germany, UK), but current prescription rates are still low. What are the next steps to increase PDT prescription and adoption?

About Us

HLTH Inc. is a dynamic community delivering unique value to the healthcare industry through a mix of unparalleled global events, inspirational content, and impact-driven initiatives.

Hyve Logo

USA Event Dates

2026 | HLTH: Nov 15 – 18 | Las Vegas | Register | Sponsor
2027 | ViVE: Mar 14 – 17 | Nashville | Be First to Know | Sponsor
2027 | HLTH: Oct 17 – 20 | Las Vegas, NV

Europe Event Dates

2027 | HLTH Europe: Jun 21 – 24 | Amsterdam | Sponsor
2028 | HLTH Europe: Jun 19 – 22 | Amsterdam

Important Notice on Hotel Scams

Any communication that claims to represent HLTH or any third party offering discounted hotel rooms or attendee lists is NOT AFFILIATED with HLTH and should be considered fraudulent. Please book your accommodations only through HLTH’s official channels to ensure authenticity and security.